论文部分内容阅读
背景利钠肽对急性心力衰竭(简称心衰)病人的预后意义业已肯定。BACH是一项15个单位参加的国际前瞻性临床试验。采用多种生物标志观察1 641例因气促来急症室求治的病人。第一终点是观察MR proADM预告病人90天死亡率是否优于NTproBNP。医生们不掌握MR proADM的情况。心衰的金标准
Background Natriuretic peptide has been affirmed in patients with acute heart failure (HF) prognosis. BACH is a 15-unit international prospective clinical trial. A wide range of biomarkers were used to observe 1 641 cases of patients who sought emergency treatment due to stroke. The first end point was to look at whether the MR proADM predicted that the 90-day mortality was superior to NTproBNP. Doctors are not familiar with MR proADM. Gold standard of heart failure